Fig. 3From: Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug actOrphan drugs for rare rheumatologic disorders – time to FDA approval. a by drug class. b by disease. Lines indicate meansBack to article page
